4.6 Review

δ-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities

Journal

TRANSLATIONAL NEURODEGENERATION
Volume 9, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s40035-019-0179-3

Keywords

AEP; Alzheimer's disease; Parkinson's disease; C/EBP beta; TrkB; TDP-43

Categories

Funding

  1. National Institute of Health [AG051538, NS105982]
  2. National Natural Science Foundation of China [81822016, 81771382, 81571249]

Ask authors/readers for more resources

Mammalian asparagine endopeptidase (AEP) is a cysteine protease that cleaves its protein substrates on the C-terminal side of asparagine residues. Converging lines of evidence indicate that AEP may be involved in the pathogenesis of several neurological diseases, including Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. AEP is activated in the aging brain, cleaves amyloid precursor protein (APP) and promotes the production of amyloid-beta (A beta). We renamed AEP to delta-secretase to emphasize its role in APP fragmentation and A beta production. AEP also cleaves other substrates, such as tau, alpha-synuclein, SET, and TAR DNA-binding protein 43, generating neurotoxic fragments and disturbing their physiological functions. The activity of delta-secretase is tightly regulated at both the transcriptional and posttranslational levels. Here, we review the recent advances in the role of delta-secretase in neurodegenerative diseases, with a focus on its biochemical properties and the transcriptional and posttranslational regulation of its activity, and discuss the clinical implications of delta-secretase as a diagnostic biomarker and therapeutic target for neurodegenerative diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available